Janux Therapeutics (JANX) Net Margin (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Net Margin of 1416.02% for Q1 2026, down 7.96% quarter-over-quarter from 1311.57% in Q3 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Net Margin (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Net Margin for 6 consecutive years, with 1416.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin changed N/A year-over-year to 1416.02%; the TTM figure through Mar 2026 stood at 2537.67% (up 613070.0% YoY), while the FY2025 annual figure was 1432.21%, up 263455.0% from the prior year.
- Net Margin eased to 1416.02% in Q1 2026 per JANX's latest filing, from 1311.57% in the prior quarter.
- Across five years, Net Margin topped out at 477.77% in Q4 2023 and bottomed at 77800.68% in Q3 2024.
- Historically, Net Margin has averaged 9503.19% across 5 years, with a median of 2680.08% in 2023.
- Annual changes were most pronounced in 2024 — Net Margin sank 7674212 bps — and 2025, when it surged 7648911 bps.
- Janux Therapeutics' Net Margin stood at 576.77% in 2022, then rose by 17 bps to 477.77% in 2023, then tumbled by 16184 bps to 77800.68% in 2024, then surged by 98 bps to 1311.57% in 2025, then retreated by 8 bps to 1416.02% in 2026.
- Business Quant data shows JANX's Net Margin at 1416.02% in Q1 2026, 1311.57% in Q3 2025, and 77800.68% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -214.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -214.01% |
| Mar 31, 2026 | -652.59% |
| Sep 30, 2025 | -243.13% |
| Sep 30, 2024 | -6,391.57% |
| Jun 30, 2024 | -66.98% |
| Mar 31, 2024 | -1,178.91% |
| Dec 31, 2023 | -477.77% |
| Sep 30, 2023 | -459.59% |
| Jun 30, 2023 | -1,656.39% |
| Mar 31, 2023 | -852.49% |
| Dec 31, 2022 | -564.67% |
| Sep 30, 2022 | -920.90% |
| Jun 30, 2022 | -714.08% |
| Mar 31, 2022 | -843.93% |
| Dec 31, 2021 | -830.20% |
| Sep 30, 2021 | -928.90% |
| Jun 30, 2021 | -1,287.55% |
| Mar 31, 2021 | -601.05% |